Department of Clinical Oncology with Onco-Hematology Laboratory


jacqueline-kelly-PeUJyoylfe4_0  helloquence-OQMZwNd3ThU_0  sarah-shaffer-O3gOgPB4sRU_0

Prof. Andrey Zaritskey, MD, DSc
Director of the Institute of Oncology and Hematology, Chief Researcher of Laboratory

Major objectives

Research aimed at studying the biological characteristics of the most common types of hematologic malignancies (chronic myelogenous leukemia, Ph-negative myeloproliferative disorders, chronic lymphocytic leukemia, acute myeloid leukemia and multiple myeloma) in order to optimize treatment approaches.

Major achievements and new technologies

  • Study of the bone marrow niche and biology of hematopoietic stem cells.
    This work has been carried out at the Institute since its foundation.
    Several publications in leading Russian hematology journals are devoted to this topic. In 2012, it was shown that co-culture of HSCs and MSCs transduced with the DLL1 gene increases the expansion of the low-differentiated fraction of CD34+ cells; a model of the bone marrow vascular niche (endothelial cells with constitutively active Akt1) was developed, and the study showed the role of hypoxia in preserving the primitive fraction of CD34+CD38- cells and high clonogenic ability of HSCs, etc.
  • Study of new prognostic markers and optimization of treatment regimens.
    The study of the dynamics of WT1 expression level, as well as other molecular markers, such as BAALC, DNMT3A, RUNX1-RUNX1T1 in acute myeloid leukemia, allowed us to determine the prognostically significant reduction degrees of gene transcription in the post-induction period. The significance of monitoring the gene expression levels in patients in clinical and hematological remission was also revealed.
    The role of molecular markers in lymphoid and myeloid neoplasms is a priority for the Institute of Hematology. The results of this research make it possible to optimize patient management, including the selection of the most effective treatment regimens, innovative drugs, as well as timely refer the patient to allogeneic hematopoietic stem cell transplantation.

Participation in international projects

From 2013 to 2017, the Institute has been participating in research carried out by an international consortium as part of the 7th EU Framework Program (SystemAge, Work Package 4). This project studied the aging of HSCs and its relationship to the development of myelodysplastic syndrome and CLL. The topic of CLL was also addressed in the study on recreating a model of the microenvironment of the lymph nodes in this disease.


  • Onco-Hematology Laboratory

The studies of Onco-Hematology Laboratory focus on the biological characteristics and optimization of treatment approaches for the most common types of hematologic malignancies: chronic myelogenous leukemia, Ph-negative myeloproliferative disorders, chronic lymphocytic leukemia, acute myeloid leukemia and multiple myeloma.

Major areas

  • CML and Ph-negative myeloproliferative disorders
  • Chronic lymphocytic leukemia
  • Acute myeloid leukemia
  • Multiple myeloma
Major publications

Dinikina, Y; Belogurova, M; Zaritskey, A; Govorov, I; Tsibizova, V; Gamzatova, Z; Pervunina, T; Komlichenko, E. Ovarian tissue cryopreservation in prepubertal patients with oncological diseases: multidisciplinary approach and outcomes.  JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE. 2019; 18: 1-8.  DOI: 10.1080/14767058.2019.1666364.

Kulemzin, S.V., Gorchakov, A.A., Chikaev, A.N., Kuznetsova, V.V., Volkova, O.Y., Matvienko, D.A., Petukhov, A.V., Zaritskey, A.Y., Taranin, A.V. VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells. 2018; 9 (10): 9021—9029. DOI: 10.18632/oncotarget.24078.

Strugov, V; Stadnik, E; Virts, Y; Andreeva, T; Zaritskey, A. Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia. ANNALS OF HEMATOLOGY. 2018; 97 (11): 2153—2161. DOI: 10.1007/s00277-018-3409-3.

Titov, A; Petukhov, A; Staliarova, A; Motorin, D; Bulatov, E; Shuvalov, O; Soond, SM; Piacentini, M; Melino, G; Zaritskey, A; Barlev, NA. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. CELL DEATH & DISEASE. 2018; 9: ID 897 (эл.рес.). DOI: 10.1038/s41419-018-0918-x.

Vasylyev, A; Molostvova, V; Rebrov, BA; Makarova, J; Zaritskey, A; Ptushkin, V; Ramazanova, R; Popovych, Y; Tsyapka, O; Pashanov, E. Standard of care and direct medical costs of the treatment of chronic lymphocytic leukemia among the adult population in Ukraine, Russia, and Kazakhstan: data from the LEUKOSPECT study. CANCER MANAGEMENT AND RESEARCH. 2017; 9: 387- 395; DOI:10.2147/CMAR.S139915.

Chanan-Khan, AA; Zaritskey, A; Egyed, M; Vokurka, S; Semochkin, S; Schuh, A; Kassis, J; Simpson, D; Zhang, JN; Purse, B; Foa, R. First-in-Man Analysis of the Relationship Between Electrical Rotors From Noninvasive Panoramic Mapping and Atrial Fibrosis From Magnetic Resonance Imaging in Patients With Persistent Atrial Fibrillation. CIRCULATION ARRHYTHMIA AND ELECTROPHYSIOLOGY. 2017; 10 (8): e004419 (эл. рес.). DOI: 1161/CIRCEP.116.004419

Elza Lomaia, Leading Researcher of Clinical Onco-Hematology Department


Уведомляем вас, что в соответствии с Федеральным законом от 06.03.2006 № 35-ФЗ «О противодействии терроризму» в Центре Алмазова введен комплекс дополнительных мер по безопасности, направленный на предотвращение террористических актов. В целях обеспечения безопасности граждан и целостности объектов инфраструктуры при посещении Центра Алмазова проводится дополнительный личный осмотр, осмотр вещей и автотранспорта. Отказ от соблюдения мер по безопасности может послужить причиной недопуска на территорию Центра Алмазова. Просим с пониманием отнестись к введенным мерам по безопасности.

С уважением, Администрация Центра Алмазова